jxg168

Jon Glass, MD

Contact Dr. Glass

909 Walnut Street
Philadelphia, PA 19107

(215) 503-7005
(215) 503-9357 fax

Most Recent Peer-reviewed Publications

  1. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment
  2. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)
  3. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma
  4. Current management of primary central nervous system lymphoma
  5. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525
  6. Reply to M.C. Chamberlain
  7. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227
  8. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas
  9. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better
  10. Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases
  11. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  12. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma
  13. A 60-year-old indian male with altered sensorium and extensive lymphoma of the scalp
  14. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  15. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
  16. Characterization and outcomes of optic nerve gliomas: A population-based analysis
  17. Intravascular lymphoma of the CNS
  18. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
  19. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas
  20. Central nervous system cancers: Clinical Practice Guidelines in Oncology™